By combining advanced vision-language AI models with real-world task analysis, researchers developed a system that can recognize cognitive sequencing errors during everyday activities like cooking. This approach moves beyond traditional assessments, offering a more realistic way to support safety, confidence, and daily functioning.
Research at Washington University in St. Louis has been recognized on the global stage, with WashU named a Focused Ultrasound Center of Excellence by the Focused Ultrasound Foundation.
NEURO360-aligned research led by Rohit V. Pappu, PhD, with Min Kyung Shinn, PhD, at WashU’s McKelvey School of Engineering is uncovering new therapeutic targets for neurodegenerative disorders such as ALS.
NEURO360‑aligned research by Muriah D. Wheelock and Brian A. Gordon at WashU Medicine received a $5 million NIH grant to study how early‑life stress affects brain aging and Alzheimer’s.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
A group of researchers from WashU in the McKelvey School of Engineering and the School of Medicine have created a new kind of fiber-optic device to manipulate neural activity deep in the brain. The device, called PRIME fiber, delivers multi-site, reconfigurable optical stimulation through a single, hair-thin implant.
A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
NEURO360 partner, C2N Diagnostics, is set to occupy just over half of the new space in WashU’s $100 million redevelopment, leaving room for other growing bioscience companies. Read the entire announcement on St. Louis Magazine’s website by clicking here.
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline with a new potential therapy, valiloxybate for treatment of narcolepsy and idiopathic hypersomnia. Read the press release at Avadel Pharmaceuticals’ website by clicking here.
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.
